OTCMKTS:PPCB Propanc Biopharma (PPCB) Stock Forecast, Price & News $0.03 0.00 (0.00%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$0.02▼$0.0350-Day Range$0.03▼$0.1252-Week Range$0.02▼$0.26Volume147,557 shsAverage Volume465,356 shsMarket Capitalization$88,447.20P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest About Propanc Biopharma (OTCMKTS:PPCB) StockPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Read More PPCB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PPCB Stock News HeadlinesAugust 15, 2023 | finance.yahoo.comPropanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, AustraliaJuly 26, 2023 | finance.yahoo.comPropanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030September 21, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.July 13, 2023 | finance.yahoo.comPropanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 ReadsJuly 5, 2023 | finance.yahoo.comPropanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid TumorsJune 30, 2023 | sg.finance.yahoo.comPPCB - Propanc Biopharma, Inc.June 28, 2023 | finance.yahoo.comPROPANC BIOPHARMA INC (PPCB) stock forecast and price targetMay 25, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in EuropeSeptember 21, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.May 23, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North AmericaMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces Reverse Stock SplitMarch 28, 2023 | finance.yahoo.comPropanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic CancerMarch 16, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor CellsMarch 14, 2023 | benzinga.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, PredictionsFebruary 23, 2023 | seekingalpha.comPPCB Propanc Biopharma, Inc.January 11, 2023 | finance.yahoo.comPropanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)December 17, 2022 | finanznachrichten.dePropanc Biopharma, Inc.: Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of JaénDecember 15, 2022 | finance.yahoo.comPropanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of JaénNovember 30, 2022 | finance.yahoo.comPropanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic CancerNovember 15, 2022 | finance.yahoo.comPropanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic CancerOctober 26, 2022 | finance.yahoo.comPropanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor ConferenceOctober 12, 2022 | finance.yahoo.comPropanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17September 29, 2022 | finance.yahoo.comPropanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027September 8, 2022 | finance.yahoo.comPropanc Biopharma Reports Significant Effects of PRP Against the Tumor MicroenvironmentAugust 23, 2022 | finance.yahoo.comPropanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery ProgramAugust 17, 2022 | finanznachrichten.dePropanc Biopharma, Inc.: Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent OfficeAugust 16, 2022 | finance.yahoo.comPropanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent OfficeSee More Headlines Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address PPCB Company Calendar Today9/21/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PPCB CUSIPN/A CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,660,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2,634.75% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($13.75) per share Price / Book0.00Miscellaneous Outstanding Shares3,288,000Free Float3,229,000Market Cap$88,447.20 OptionableNot Optionable Beta1.59 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. James Nathanielsz (Age 49)Exec. Chairman, CEO, CFO, Treasurer & Sec. Comp: $349.38kDr. Julian Norman Kenyon ChB (Age 75)M.D., MB, Chief Scientific Officer, CTO & Director Comp: $35.99kProf. Klaus KutzChief Medical Officer & Member of Scientific Advisory BoardKey CompetitorsRespireRx PharmaceuticalsOTCMKTS:RSPIDAsterias BiotherapeuticsNYSEAMERICAN:ASTCodiak BioSciencesNASDAQ:CDAKQDiadexusOTCMKTS:DDXS9 Meters BiopharmaNASDAQ:NMTRView All Competitors PPCB Stock - Frequently Asked Questions How have PPCB shares performed in 2023? Propanc Biopharma's stock was trading at $0.60 at the beginning of 2023. Since then, PPCB shares have decreased by 95.5% and is now trading at $0.0269. View the best growth stocks for 2023 here. When did Propanc Biopharma's stock split? Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR), Cronos Group (CRON), CRISPR Therapeutics (CRSP), Petroteq Energy (PQEFF), Xerox (XRX), Aurora Cannabis (ACBFF), Amgen (AMGN), Amarin (AMRN) and Aphria (APHQF). What is Propanc Biopharma's stock symbol? Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB." How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Propanc Biopharma's stock price today? One share of PPCB stock can currently be purchased for approximately $0.03. How much money does Propanc Biopharma make? Propanc Biopharma (OTCMKTS:PPCB) has a market capitalization of $88,447.20. How can I contact Propanc Biopharma? Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The official website for the company is www.propanc.com. The company can be reached via phone at (139) 882-0780, via email at irteam@propanc.com, or via fax at 61 03 9882 9969. This page (OTCMKTS:PPCB) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.